Phase i study of 'dose-dense' pemetrexed plus carboplatin/radiotherapy for locally advanced non-small cell lung carcinoma

Table 3 Treatment Response and Outcomes Data

Patient	Dose Level	Initial Local response	Distant Metastases	Survival Status
1 TJ	1	NR/SD	None	AWD @ 40 mo.
2 ST	1	PR	Diffuse Mets	DOD @ 34 mo.
3 LM	1	PR	Diffuse Mets	DOD @ 15 mo.
4 SR	1	CR	Diffuse Mets	DOD @ 29 mo.
5 MW	1	PR	Mets at presentation	DOD @ 6 mo.
6 SR	1	CR	None	NED @ 26 mo.
7 PH	2/-1	CR	None	AWD @ 26 mo.
8 JD	2/-1	PD*	None	NED @ 27 mo.
9 JB	1A	CR	None	NED @ 24 mo.
10 BS	1A	PR	Mets at presentation	DOD @ 9 mo.
11 ES	1A	PR	Mets at presentation	DOD @ 6 mo.
12 JB	1A	NA	NA	DID/DOC @ 3 mo.
13 EH	1A	PR	Mets at presentation	DOD @ 6 mo.
14 ML	1A	PR	None	NCRM @ 9 mo.
15 CN	1A	PR	None	AWD @ 18 mo.
16 UG	1A	CR	None	AWD @ 18 mo.

NR/SD: No Response/Stable Disease
PR: Partial Response
CR: Complete Response
PD*: Progressive Disease (one patient had PD just outside of the radiotherapy field edge)
NA: Not Assessable - one patient is not assessable or evaluable due to early (possibly treatment related) death.
AWD: Alive with Disease
DOD: Died of Disease
NED: No Evidence of (Active) Disease
DID/DOC: Died of intercurrent Disease and/or treatment Complications
NCRM: Non-cancer related mortality (one patient died of a MI while NED)

ISSN: 1748-717X